Abstract
The high-affinity mammalian brain l-proline transporter (PROT) belongs to the GAT1 gene family, which includes Na- and Cl-dependent plasma membrane carriers for neurotransmitters, osmolites, and metabolites. These transporters couple substrate flux to transmembrane electrochemical gradients, particularly the Na gradient. In the nervous system, transporters clear synapses and help to replenish transmitters in nerve terminals. The localization of PROT to specific excitatory terminals in rat forebrain suggests a role for this carrier in excitatory transmission (Renick et al., 1999). We investigated the voltage regulation and electrogenicity of this novel transporter, using human embryonic kidney (HEK) 293 cells stably transfected with rat PROT cDNA. In physiological solutions between −140 and −40 mV, l-proline (PRO) and its six-member ring congener l-pipecolate (PIP) induced inward current. The current–voltage relationship and the variance of current fluctuations were similar for PRO- and PIP-induced current, and the ratio of induced variance to the mean current ranged from 20 to 60 fA. Des-Tyr-Leu-enkephalin (GGFL), a competitive peptide inhibitor of PROT, reduced the rat PROT-associated current to control levels. GGFL alone did not elicit currents, and the GGFL-sensitive substrate-induced current was absent in nontransfected cells. Finally, GGFL inhibited PROT-mediated transport only when applied to the extracellular face of PROT. These data suggest that (1) PROT uptake is electrogenic, (2) individual transporter currents are voltage-independent, and (3) GGFL is a nonsubstrate inhibitor that interacts either with an extracellular domain of PROT or in an externally accessible pore.
Keywords: proline, pipecolic acid, transporter, enkephalin, voltage-clamp, uptake, current, HEK-293 cells
A mammalian brain high-affinityl-proline transporter (PROT) was cloned from a rat forebrain cDNA library on the basis of amino acid sequence conservation between GABA and norepinephrine transporters (Fremeau et al., 1992). The PROT cDNA encodes a 68 kDa glycosylated protein that exhibits 42–50% amino acid sequence identity with a gene family of Na- and Cl-dependent plasma membrane transports proteins that mediate high-affinity uptake of neurotransmitters (norepinephrine, dopamine, serotonin, GABA, glycine), osmolites (taurine, betaine), and the metabolite creatine (Shafqat et al., 1993; Velaz-Faircloth et al., 1995; Miller et al., 1997a,b). These transporters use transmembrane electrochemical gradients to transport substrates across the plasma membrane. They are also critical targets for therapeutic and pathological alterations of synaptic function (for review, seeKanner, 1989; Amara and Kuhar, 1993; Rudnick and Clark, 1993; Blakely et al., 1994; Lester et al., 1994). The brain-specific expression of PROT in human (Shafqat et al., 1995) and rat (Velaz-Faircloth et al., 1995) tissues is consistent with a unique physiological role for this transporter in the mammalian CNS.
The pharmacological specificity, ion dependence, and kinetics of the cloned transporter expressed in non-neural cells (Fremeau et al., 1992,1996; Shafqat et al., 1995) are similar to the corresponding properties of the high-affinity component of synaptosomal l-proline uptake (Bennett et al., 1972; Peterson and Raghupathy, 1972; Balcar et al., 1976; Nadler, 1987). These properties distinguish PROT from the other widely expressed Na-dependent plasma membrane carriers that transport l-proline (PRO), including the intestinal brush border “imino” carrier (Stevens et al., 1984) and the system “A” and system “ASC” neutral amino acid carriers (Christensen, 1990). In situ hybridization of rat brain sections and cultured hippocampal neurons demonstrated that PROT mRNA is expressed by subpopulations of putative glutamatergic neurons in rat brain (Fremeau et al., 1992; Velaz-Faircloth et al., 1995). Recently, Crump et al. (1999) observed that the PROT protein is localized to a subset of excitatory terminals in cultured rat hippocampal neurons. Furthermore, ultrastructural studies showed that PROT is localized selectively to a subset of presynaptic axon terminals, forming asymmetric excitatory-type synapses typical of glutamatergic synapses (Renick et al., 1999). These findings raise the possibility of a specialized role for PROT and its presumed natural substrate,l-proline, in the modulation of excitatory synaptic transmission in specific excitatory pathways within the CNS. High-affinity l-proline uptake may regulate the ability of extracellular proline to potentiate excitatory transmission at those synapses that express PROT (Cohen and Nadler, 1997).
To gain biophysical insight into the nature of PROT-mediated transport processes, we established the cell line HP-21 by stably transfecting human embryonic kidney 293 (HEK-293) cells with rat PROT cDNA (Fremeau et al., 1992). The HP-21 cell line is suitable for biochemical analysis, radiolabeled flux studies, and patch-clamp recording techniques. Electrophysiological measurements reveal that rat PROT (rPROT) is electrogenic; however, individual transporter events are not voltage-dependent. We also suggest that several previously identified inhibitors of high-affinity l-proline uptake, includingl-pipecolate (PIP), an endogenous brainl-lysine metabolite (for review, see Giacobini et al., 1980), are likely PROT substrates, and we propose a Na- and Cl-dependent stoichiometric mechanism for PRO and PIP transport. Finally, we demonstrate that the competitive peptide inhibitor Des-Tyr-Leu-enkephalin (GGFL) inhibits PROT-mediated transport processes only from the outside.
MATERIALS AND METHODS
rPROT stable cell lines and tissue culture. AnEcoRI/XbaI fragment of the rat PROT cDNA containing the entire protein coding sequence was released from pBluescript KSII(−) (Fremeau et al., 1992) and subcloned into EcoRI/XbaI-digested pcDNA3 (Invitrogen, San Diego, CA) such that PROT expression was under the control of enhancer–promoter sequences from the immediate-early gene of the human cytomegalovirus (CMV). To generate stably transfected cell lines, we transfected the pcDNA3–PROT mammalian expression construct by calcium phosphate coprecipitation (Invitrogen) into HEK-293 cells at ∼50% confluence. The cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum and 50 μg/ml gentamycin. After 3 d the transfected cells were switched to medium containing 250 μg/ml Geneticin (G418; Life Technologies, Gaithersburg, MD). Resistant colonies were isolated 2 weeks later by using sterile cloning rings, and individual resistant cells were used to generate clonal lines. Multiple lines exhibited GGFL-sensitive [3H]-PRO uptake and immunoreactive PROT protein. Clonal line HP-21 was used in all of the experiments reported here. The culture of HEK-293 cells stably transfected with rat PROT cDNA (HP-21 cells) was as follows: HP-21 cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mml-glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml). Trypsin-released cells were seeded in 24-well cell culture plates at 1–1.5 × 105 cells/well and allowed to grow for 48 hr before the transport measurements were done.
Transport assays. Measurements were performed in triplicate by incubating the HP-21 cells for 10 min at 37°C, with [3H]-PRO in 0.5 ml of Krebs–Ringer’s–HEPES–Tris (KRHT) buffer, pH 7.4, containing (in mm) 120 NaCl, 4.7 KCl, 2.2 CaCl2, and 10d-glucose. The concentration of HEPES was 10 mm, and the concentration of Tris was 5 mm. For the time course of uptake, we used 50 nm[3H]-PRO to determine the incubation period for uptake (10 min). This introduces an approximation, because higher concentrations will fall off faster from their initial velocities. The consequence is to underestimate Vmax by as much as 20%. Thus we underestimated the coupled current.
Assays were terminated by removing the radiolabeled PRO and by washing the cells rapidly three times with 1 ml of ice-cold KRHT buffer. Cells were solubilized with 1 ml of Optiphase scintillant (Wallac, Gaithersburg, MD), and accumulated radioactivity was quantified by direct scintillation spectrometry with a Microbeta microplate scintillation counter (Wallac). Inhibitors were added 10 min before the addition of labeled substrates in the inhibition studies, whereas unlabeled substrates were added simultaneously with labeled substrates in the kinetic studies. The cells were counted each time just before the assay. Substrate Km andVmax were determined by nonlinear least-square fits (Kaleidagraph, Synergy Software, Reading, PA) with the generalized Hill equation: V = Vmax[S]n/(Kmn+ [S]n), where V is the transport velocity, [S] is the substrate concentration, and n is the Hill coefficient. InhibitorKi values were determined by nonlinear least-squares fits, using two-parameter logistic equations: the percentage of specific PRO transport remaining = 100/[1 + (IC50/[I])n]. The IC50 is the concentration of inhibitor giving 50% inhibition, [I] is the inhibitor concentration, andn is the slope (Hill coefficient). To determineKi values, we adjusted IC50 values to account for substrate concentration (Cheng and Prusoff, 1973). Data are represented as the means ± SEM of six independent measurements on three separate batches of cells. The dependence of [3H]-PRO on Na and Cl concentration was determined by the method of Clark and Amara (1994). The ionic concentrations in KRHT buffers were varied by mixing the NaCl-containing buffer with those that lacked Na or Cl. After 15 min preincubation, [3H]-PRO (0.05 ml) was added to each well (50 nm final concentration). Transport in each well was stopped after 10 min by three 1 ml washes with ice-cold KRHT solutions (without glucose) that contained the same Na and Cl concentration as during preincubation and transport. After the last wash, 1% SDS was added to each well. After solubilization a small aliquot of each solubilized cell mixture was set aside for protein determination (Bio-Rad DC Protein Assay Kit, Richmond, CA). The rest was mixed with scintillation fluid for scintillation counting. We defined uptake into nontransfected HEK cells as background. Each assay was performed in triplicate, and mean specific uptake ± SEM was determined and expressed as pmol/mg protein per 10 min.
Electrophysiology. Stably transfected cells have advantages for electrophysiology over transiently transfected cells. They express more uniformly, have more negative resting potentials (−30 to −50 mV), and form tighter seals (>20 GΩ) for whole-cell voltage clamp than, for example, transiently transfected HeLa cells (Risso et al., 1996). Before electrical recording, parental or stably transfected cells were plated at a density of 105 per 35 mm culture dish, and attached cells were washed three times with bath solution at room temperature. The normal bath contained (in mm): 130 NaCl, 1.3 KCl, 1.3 KH2PO4, 0.5 MgSO2, 1.5 CaCl2, 10 HEPES, and 34 dextrose. The solution was adjusted to pH 7.35 and 300 mOsm with 1 m NaOH and dextrose. Pipette solutions for the whole-cell recording contained (in mm): 130 KCl, 0.1 CaCl2, 2 MgCl2, 1.1 EGTA, 10 HEPES, and 30 dextrose adjusted to pH 7.35 and 270 mOsm. Free Ca in the pipette was calculated as 0.1 μm. To confirm specificity, we recorded substrate-induced currents in the absence and presence of GGFL. Electrodes were pulled with a Programmable puller (Sachs-Flaming, PC-84). An Axopatch 200A or EPC7 amplifier band limited at 5000 Hz was used to measure current. Series conductance was 0.1 μS or greater, and cell capacitance was 25–80 pF, implying 2500–8000 μm2 surface area. HP-21 are clonal cell lines, and expression levels are constant to within a factor of two; however, with increasing passages there is decreasing expression. This prevented normalization of the current to surface area. Voltage steps ranged from −140 to −20 mV and lasted 500 msec. Test pulses were separated by −20 mV holding potentials for 4 sec. Values for steady-state currents were taken between 400 and 500 msec after the step. Data were stored digitally on a VCR and analyzed on a Nicolet 4094 oscilloscope and an IBM-AT or Compaq Pentium computer, using instrumentation and programs written by W. N. Goolsby (Emory University, Atlanta, GA) or using pClamp 6.0.
RESULTS
Multiple colonies of rat PROT cDNA-transfected HEK-293 cells were isolated after Geneticin (G418) selection and assayed for GGFL-sensitive [3H]-PRO uptake. One of these lines (HP-21) was expanded and analyzed for expression of PROT by immunolabeling, radiolabeled flux studies, and electrophysiological measurements. As documented in Renick et al. (1999), affinity-purified antipeptide antibodies directed against the N or C terminus of the rat PROT protein routinely recognize two specific immunoreactive bands on immunoblots of HP-21 membranes: an intense, broad immunoreactive band centered at ∼69 kDa and a weaker immunoreactive band centered at ∼53 kDa. No specific labeling is observed in parental HEK membranes or when immunoblots are exposed to preimmune serum. Preabsorption of either antibody with the peptide used for its purification abolishes all immunolabeling (for a sample blot, see Renick et al., 1999). We previously observed that the anti-PROT antibodies recognize a single broad immunoreactive band centered at ∼68 kDa on immunoblots of rat and human brain tissue (Shafqat et al., 1995; Velaz-Faircloth et al., 1995; Renick et al., 1999). Deglycosylation of rat brain membranes with PNGase F reduced the apparent molecular mass of the mammalian brain PROT protein from ∼68 to ∼53 kDa, a size that corresponds to that of the primary PROT translation product determined by in vitro-coupled transcription and translation of the rat PROT cDNA in the absence of microsomes (Velaz-Faircloth et al., 1995; Renick et al., 1999). On the basis of these findings we conclude that the ∼69 kDA band observed in HP-21 membranes represents the mature N-glycosylated PROT protein, whereas the ∼53 kDa band represents the unglycosylated primary translation product. Interestingly, although the apparent molecular mass of the major PROT immunoreactive band varies between experiments, depending on the percentage of acrylamide in the SDS-PAGE gel and the particular batch of molecular weight standards, a clear difference in electrophoretic mobilities is observed between PROTs expressed in HEK-293 stable transfectants (HP-21) and the immunoreactive rat brain PROT run side by side on the same 8% SDS-PAGE gel (Renick et al., 1999). These results suggest that the primary PROT translation product is subject to differential N-glycosylation in HEK-293 cells versus rat brain.
HP-21 cells transport proline
HP-21 cells accumulated PRO in a time- and dose-dependent manner (Fig. 1). PRO uptake is approximately linear up to 20 min (Fig. 1A). To explore the functional properties of PROT, we performed kinetic analysis of [3H]-PRO uptake. Nonlinear least-squares curve fitting of saturation data was accomplished by using the generalized Hill equation (see Materials and Methods). Proline uptake follows saturable kinetics, with Km = 20.12 ± 3.14 μm and Vmax = 892.26 ± 39.03 pmol/105 cells per 10 min (Fig.1B). The Eadie–Hofstee transformation yields a linear curve consistent with a single high-affinity interaction with an apparent Km of 21 μm (Fig.1C). In contrast to the endogenous low-affinity PRO uptake observed in nontransfected HEK cells, which have aKm of ∼350 μm (Shafqat et al., 1995), HP-21 cells were capable of saturable uptake at low micromolar proline concentrations.
Inhibition of l-proline uptake by leu-enkephalin and its des-tyrosyl derivative
To characterize uptake, we tested the ability of unlabeled PRO and several structurally related compounds to compete for [3H]-PRO uptake. Unlabeled PRO and its six-member ring congener, PIP, another possible substrate of PROT (Fremeau et al., 1992; Shafqat et al., 1995), produced a concentration-dependent reduction of [3H]-PRO uptake in HP-21 cells. The apparent Ki values for these compounds were, respectively, 16.10 ± 1.92 and 17.44 ± 1.58 μm (Fig. 2). PROT exhibits significant amino acid sequence homology with other members of the GAT1 gene family but is unique in demonstrating a particular affinity for enkephalins. Fremeau et al. (1996) reported that leucine-enkephalin (YGGFL) and its des-tyrosyl derivative (GGFL) specifically inhibited high-affinity PRO uptake without affecting the plasma membrane transporter activity of several other members of the gene family. Here, we demonstrate that YGGFL and its des-tyrosyl derivative GGFL produced a concentration-dependent reduction of [3H]-PRO uptake in HP-21 cells (Fig. 2). GGFL was more potent (Ki = 3.51 ± 0.67 μm) than YGGFL (Ki = 9.44 ± 1.88 μm) at inhibiting PRO uptake in the HP-21 cells.
Ion dependence of [3H]-l-proline uptake
Isotonic substitution of extracellular Na ions with Li or extracellular Cl ions with isethionate abolished PRO uptake. This inhibition was reversible. In contrast, endogenous low-affinity transport of PRO is dependent on extracellular Na, but not on extracellular Cl (Shafqat et al., 1995). Saturation curves for the dependence of [3H]-PRO uptake on Na and Cl concentration are presented in Figure 3,A and B. Specific uptake by HP-21 cells increased with Na concentration in a sigmoidal manner, with an apparentKm = 40.7 ± 1.7 mm. In contrast, the relationship between specific uptake and Cl concentration was hyperbolic, with an apparent Km = 7 ± 1 mm. The Hill coefficients for Na and Cl were set to the values n = 2 and n = 1, respectively, after initial nonlinear trials that resulted in values close to these. These data are consistent with a substrate stoichiometry for rPROT of 1 PRO: 2 Na: 1 Cl and a net transfer of one elementary charge per transport cycle at physiological pH.
Proline induces a GGFL-sensitive current in HP-21 cells
Figure 4 shows data from a HP-21 cell in the whole-cell voltage-clamp mode. The holding potential was −40 mV and the test potential was −140 mV for 500 msec. The raw data were obtained at room temperature and are neither leak-subtracted nor capacity-compensated. PRO (40 μm) had no effect on parental cells. These data demonstrate that PRO increases the steady-state component of the current and that GGFL blocks this induced current to control levels. PRO-induced current is defined as the current in the presence of PRO minus the current without PRO (control: Cont). The inset shows the effect of 40 μm PIP at −120 mV. GGFL blocks PIP-induced current with equal effectiveness (n = 4). GGFL has no effect on the pre-steady-state control current, and, similarly, control–proline curves show no pre-steady-state effects. Instead, the apparent difference between the on and the off transients represents similar activation/relaxation kinetics of the steady-state currents. Interestingly, two molecules that previously were shown to inhibit PRO uptake in PROT-transfected HeLa cells, l-norleucine and sarcosine (Fremeau et al., 1992; Shafqat et al., 1995), also were able to generate GGFL-sensitive inward current at negative voltages (100 μm bath substrate concentration; data not shown). These data support the conclusion that PROT-mediated PRO uptake is electrogenic. Because PRO, PIP, l-norleucine, and sarcosine are able to induce similar currents through the proline transporter, we suggest that these substrates have a similar mechanism of action and a common permeation pathway. On the other hand, the competitive peptide inhibitors GGFL and YGGFL (data not shown for the latter) themselves are unable to induce currents but inhibit substrate-induced currents. These data support the suggestion from previous data that GGFL and YGGFL are nontransported inhibitors of PROT, i.e., antagonists (Fremeau et al., 1996).
I–V curves and mean–variance analysis for proline and l-pipecolate
Figure 5, A andB, compares current–voltage I–V curves for PRO- and PIP-induced currents obtained from parallel dishes of transfected cells. The I–V relationships were defined by plotting the (background-subtracted) substrate-induced currents against the test voltage. We used concentrations of ∼2× the Kmfor uptake, measuring the average substrate-induced current between 400 and 500 msec during the test pulse. The I–V for PRO and PIP are similar in shape and absolute value, providing circumstantial evidence for a mutual mechanism of uptake; however, we have not explored whether PRO and PIP compete for similar binding sites or occlude each other’s currents. To investigate whether charge transported through PROTs is uncoupled (Galli et al., 1996, 1997;Larsson et al., 1996; Lester et al., 1996; Sonders and Amara, 1996), we investigated the elementary events that underlie the PRO-induced currents. Figure 5, C and D, shows results obtained from current fluctuations induced by PRO and PIP, respectively. Between −140 and −60 mV, the value ofi(1 − p) for PRO is 31.4 ± 17.7 fA and for PIP is 56.4 ± 48.7 fA (mean ± SD), with a slope not significantly different from zero for either substrate (p < 0.05). Therefore, the >2× increase of substrate-induced current observed in the same voltage range does not result from an increase in the elementary current, and there is no statistical correlation between the macroscopic and microscopic current–voltage relations (r < 0.01). The subtraction procedure that we used compares the variance with and without PRO or PIP. For this analysis we selected cells that displayed no leak current, i.e., GGFL returned the traces to the control value. Unlike norepinephrine transporters (Galli et al., 1996, 1998), there is no significant difference in control variance or in transient currents in the presence or absence of inhibitor.
The action of GGFL is membrane side-specific
Although it is evident that GGFL blocks PRO uptake and PRO-induced current when added to the outside, it is unclear whether its action, or the action of any transporter antagonist, is sided. To evaluate whether GGFL inhibits PROT at an internal site, we performed experiments in which high concentrations of GGFL were perfused into the cell. When the electrodes were filled with 1 mm GGFL in intracellular buffer, application of 40 μm PRO to the bath induced an inward current, as shown in Figure6A. Application of external GGFL (100 μm) blocked this current. In parallel experiments with dissolved green fluorescent protein (GFP) in the pipette, there was rapid and direct access of the pipette solution to the interior of the cell as observed by fluorescence (data not shown). Nevertheless, to insure that the GGFL entered the cell, we waited 15 min after forming the whole-cell configuration. Externally applied substrate-induced currents were recorded up to 45 min after the seal was broken. These data support the hypothesis that GGFL binds to an external site that is unavailable from the intracellular compartment. The magnitude and voltage dependence of the (external) GGFL-sensitive PRO-induced current is similar to I–V values obtained in the presence of GGFL in the intracellular compartment (Fig.6B). Thus GGFL in the cytoplasmic compartment does not affect the ability of the substrate to induce PROT-mediated, voltage-dependent inward current.
DISCUSSION
In vitro flux assays demonstrate that the transport of PRO into the presynaptic terminals is Na-dependent (Fremeau et al., 1992, 1996). Our uptake data are consistent with a model in which rPROT has a stoichiometry of 1 PRO: 2 Na: 1 Cl. The coupling most likely occurs when PRO and the cotransported ions bind the transporter on the external side with an unknown sequence of events. Considering the stoichiometry of the individual transporter events, rPROT would move one elementary charge per transport cycle at physiological pH. Uptake therefore would generate an inward current proportional to the number of transporters present on the cell surface and the rate of transport. Proline transport has been studied previously only with radiolabeled flux assays in which the membrane voltage is not controlled, and we present similar data in the present paper. Electrogenic transport generating inward current mandates depolarization, which with substrate accumulation possibly could inhibit uptake. Thus the shapes of the uptake curves may not reflect entirely the fundamental properties of the transport protein. Moreover, flux assays depend on radiolabeled compounds that are not always available, as in the case ofl-pipecolate. We addressed these issues by studying the substrate-induced current with the patch-clamp technique, under the assumption that uptake and current are related. Using the transport-associated current as an indicator of PROT activity, we were able to assay function under defined ionic composition and transmembrane voltage.
We engineered a cell line, HP-21, by stably transfecting HEK-293 cells with rPROT cDNA. These cells demonstrate Na- and Cl-dependent PRO uptake that saturates at micromolar concentrations and has a Hill coefficient near 1 for l-proline. GGFL and YGGFL added externally block this transport process. Parallel incubation with unlabeled PRO and PIP demonstrate that both substrates inhibit the transport of radiolabeled l-proline with similar potency. If we assume a stoichiometry of 1 PRO: 2 Na: 1 Cl (Q = 1) and convert a nominal 500 pmol/106 cells per minute (see Fig. 1) to charges per second, one cell would generate <1 pA net inward current. In Figure 5, A and B, we show that both PRO and PIP induce an inward current of approximately −5 pA at −40 mV and −20 pA at −140 mV. Note, however, that cells are selected individually for high currents and that voltage is clamped at negative potentials, which is likely to promote uptake. In contrast, uptake velocities represent the average from thousands of unclamped cells. These differences between current and uptake measurements may explain the disparity between recorded and calculated current. In any case, it is clear that PROTs contrast markedly with NETs and SERTs, which may generate 100× the predicted coupled current (Galli et al., 1996, 1997).
At concentrations of ∼2× the Km for uptake and at −120 mV, PRO or PIP could induce −20 pA of current. This may be indicative of the previously suggested voltage dependence of the PRO uptake process (Miller et al., 1997a). To test whether the elementary charge transfer changes with voltage, we analyzed the PRO-induced current fluctuations at different potentials. The ratio of variance to mean, ς2/I =i(1 − p), measures the size of the elementary transport event (Galli et al., 1996). For PROTs this ratio is small (tens of fAs) compared with norepinephrine transporters (hundreds of fAs), and in PROTs the ratio is approximately independent of voltage between −140 and −60 mV. PROT currents apparently reverse at membrane potentials between −10 to −30 mV; however, there is considerable error in measurements near the reversal potential and therefore large variability in the data. Some cells had a leak current (PROT-associated current as revealed by GGFL in the absence of PRO), whereas other cells did not. Except for these differences, which we attribute to cell-to-cell variation, substrate-induced currents and current fluctuations are similar in PRO or PIP. The variance–mean ratio suggests elementary events of quantal size i ∼0.01 pA, approximately one-tenth the amplitude of the analogous event in hNET or dSERT (Galli et al., 1996, 1997). The voltage-dependent current likely is related to a voltage-dependent turnover of a coupled transporter rather than voltage-dependent stoichiometry. Moreover, PRO and PIP currents show similar voltage sensitivity at the macroscopic (whole-cell I–V curve) and microscopic (single transporter, ς2/I–V curve) levels, consistent with a common mechanism for the action of these two substrates. GGFL and YGGFL block both the transport process and the substrate-induced inward current, but they do not themselves induce a transporter-associated current. These data support the hypothesis that GGFL and YGGFL are nontransported PROT antagonists.
We also obtained data in support of the hypothesis that enkephalin-mediated block of the transporter process is sided. Figure 6demonstrates that GGFL does not inhibit PRO-induced currents when applied from the inside of the cell, suggesting that the GGFL-binding site faces only the extracellular compartment. This topologically specific inhibition may represent an important physiological interaction between enkephalins and mammalian PROTs (for review, seeFremeau et al., 1996). Enkephalins are stored and released from large dense-cored vesicles in the CNS (Sesack and Pickel, 1992). The concentration of enkephalins in these vesicles is ∼1 mm, and, given the geometry of excitatory synapses, the concentration of enkephalin bathing PROTs could be >10 μm (Chen et al., 1995), i.e., near the range that inhibits the proline transporter. Our data show that the peptide fragment GGFL retains the ability to inhibit proline uptake and proline-induced current. Because enkephalins are degraded by enzymatic hydrolysis generating the des-tyrosyl derivative, we infer that inhibition of proline uptake may persist well after the opioid actions of the enkephalins.
In summary, we have characterized a stable rat PROT-expressing mammalian cell line that is suitable for radiometric and biophysical techniques. Our experiments are consistent with a coupling model of 1 PRO: 2 Na: 1 Cl. The magnitude of the substrate-induced current at resting membrane potentials is close to the predicted size of the hypothetical current calculated from Vmax values for PRO uptake. Thus, unlike other transporters in this gene family, the proline transporter does not appear to mediate large, uncoupled currents. The putative endogenous substrate, l-proline, and its structurally related congener, l-pipecolate, show similar affinity and efficacy for PROT. Moreover, the level of the substrate-induced current is similar for PRO and PIP, further supporting the hypothesis that these substrates activate PROT by similar mechanisms. This conclusion is sustained by fluctuation analysis of the elementary events associated with the substrate-induced current. We conclude that PROT is electrogenic and that PRO, PIP,l-norleucine, and sarcosine are substrates of PROT. Specifically, we have shown that PIP is either a substrate for the transporter or a rare antagonist of neurotransmitter uptake capable of inducing an inward current. Using the patch-clamp technique in whole-cell configuration, we demonstrated that YGGFL and GGFL are transport blockers and identified the side of action of GGFL. Finally, unlike other members of this gene family subject to similar biophysical analysis, rPROT expressed in HEK-293 cells apparently lacks excess uncoupled current. Instead, our results indicate that rPROT behaves as a classical transporter with fixed stoichiometry.
Footnotes
This work was supported by a National Alliance for Research on Schizophrenia and Depression Young Investigator Award (A.G.) and National Institutes of Health Grants NS-33373 (L.J.D.) and NS-32501 (R.T.F.). We thank Dr. Barbara Domin for her assistance in generating the HP-21 cell line and Dawn Borromeo for her invaluable help in maintaining cell lines, preparing solutions, and other technical assistance.
Correspondence should be addressed to Dr. Louis J. DeFelice, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600.
REFERENCES
- 1.Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci. 1993;16:73–93. doi: 10.1146/annurev.ne.16.030193.000445. [DOI] [PubMed] [Google Scholar]
- 2.Balcar VJ, Johnston GAR, Stephenson AL. Transport of l-proline by rat brain slices. Brain Res. 1976;102:143–152. doi: 10.1016/0006-8993(76)90580-1. [DOI] [PubMed] [Google Scholar]
- 3.Bennett JP, Logan WJ, Snyder SH. Amino acid neurotransmitter candidates: sodium-dependent high affinity uptake by unique synaptosomal fractions. Science. 1972;178:997–999. doi: 10.1126/science.178.4064.997. [DOI] [PubMed] [Google Scholar]
- 4.Blakely RD, DeFelice LJ, Hartzell HC. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol. 1994;196:263–281. doi: 10.1242/jeb.196.1.263. [DOI] [PubMed] [Google Scholar]
- 5.Chen L, Gu Y, Huang LY. The mechanism of action for the block of NMDA receptor channels by the opioid peptide dynorphin. J Neurosci. 1995;15:4602–4611. doi: 10.1523/JNEUROSCI.15-06-04602.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
- 7.Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43–77. doi: 10.1152/physrev.1990.70.1.43. [DOI] [PubMed] [Google Scholar]
- 8.Clark JA, Amara SG. Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence. Mol Pharmacol. 1994;46:550–557. [PubMed] [Google Scholar]
- 9.Cohen SM, Nadler JV. Proline-induced potentiation of glutamate transmission. Brain Res. 1997;761:271–282. doi: 10.1016/s0006-8993(97)00352-1. [DOI] [PubMed] [Google Scholar]
- 10.Crump FT, Fremeau RT, Jr, Craig AM. Brain-specific, high-affinity l-proline transporter: preferential localization to a subset of excitatory nerve terminals in cultured rat hippocampal neurons. Mol Cell Neurosci. 1999;13:25–29. doi: 10.1006/mcne.1998.0727. [DOI] [PubMed] [Google Scholar]
- 11.Fremeau RT, Caron MG, Blakely RD. Molecular cloning and expression of a high-affinity PRO transporter expressed in putative glutamatergic pathways of rat brain. Neuron. 1992;8:915–926. doi: 10.1016/0896-6273(92)90206-s. [DOI] [PubMed] [Google Scholar]
- 12.Fremeau RT, Velaz-Faircloth M, Miller JW, Henzi VA, Cohen SM, Nadler JV, Shafqat S, Blakely RD, Domin B. A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high-affinity l-proline transporter. Mol Pharmacol. 1996;49:1–9. [PubMed] [Google Scholar]
- 13.Galli A, Blakely R, DeFelice LJ. Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci USA. 1996;93:8671–8676. doi: 10.1073/pnas.93.16.8671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Galli A, Petersen CI, deBlaquiere M, Blakely RD, DeFelice LJ. Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin-gated ion channel. J Neurosci. 1997;17:3401–3411. doi: 10.1523/JNEUROSCI.17-10-03401.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Galli A, Blakely RD, DeFelice LJ. Patch-clamp and amperometric recordings from norepinephrine transporters: channel activity and voltage-dependent uptake [see comments, Proc Natl Acad Sci USA 95:12737–12738]. Proc Natl Acad Sci USA. 1998;95:13260–13265. doi: 10.1073/pnas.95.22.13260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Giacobini E, Nomura Y, Schmidt-Glenewinkel T. Pipecolic acid: origin, biosynthesis, and metabolism in the brain. Cell Mol Biol. 1980;26:135–146. [PubMed] [Google Scholar]
- 17.Kanner BI. Ion-coupled neurotransmitter transport. Curr Opin Cell Biol. 1989;1:735–738. doi: 10.1016/0955-0674(89)90042-2. [DOI] [PubMed] [Google Scholar]
- 18.Larson HP, Picaud SA, Werblin FS, Lecar H. Noise analysis of the glutamate-activated current in photoreceptors. Biophys J. 1996;70:733–742. doi: 10.1016/S0006-3495(96)79613-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lester HA, Mager S, Quick MW, Corey JL. Permeation properties of neurotransmitter transporters. Annu Rev Pharmacol Toxicol. 1994;34:219–249. doi: 10.1146/annurev.pa.34.040194.001251. [DOI] [PubMed] [Google Scholar]
- 20.Lester HA, Cao Y, Mager S. Listening to neurotransmitter transporters. Neuron. 1996;17:807–810. doi: 10.1016/s0896-6273(00)80213-5. [DOI] [PubMed] [Google Scholar]
- 21.Miller JW, Kleven DT, Domin BA, Fremeau RT., Jr . Cloned sodium- (and chloride-) dependent high-affinity transporter for GABA, glycine, proline, taurine, and creatine. In: Reith MEA, editor. Neurotransmitter transporters. Humana; Totowa, NJ: 1997a. pp. 101–150. [Google Scholar]
- 22.Miller JW, Modjarrad K, Fremeau RT., Jr Transport properties of the high-affinity l-proline transporter (PROT) determined in membrane vesicles with rPROT cDNA. Soc Neurosci Abstr. 1997b;23:135. [Google Scholar]
- 23.Nadler JV. Sodium-dependent proline uptake in the rat hippocampal formation: association with ipsilateral commissural projections of CA3 pyramidal cells. J Neurochem. 1987;49:1155–1160. doi: 10.1111/j.1471-4159.1987.tb10006.x. [DOI] [PubMed] [Google Scholar]
- 24.Peterson NA, Raghupathy E. Characteristics of amino acid accumulation of synaptosomal particles isolated from rat brain. J Neurochem. 1972;19:1423–1438. doi: 10.1111/j.1471-4159.1972.tb05086.x. [DOI] [PubMed] [Google Scholar]
- 25.Renick S, Kleven D, Chan J, Stenius K, Milner TA, Pickel VM, Fremeau RT., Jr The mammalian brain, high-affinity l-proline transporter is preferentially enriched in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J Neurosci. 1999;19:21–33. doi: 10.1523/JNEUROSCI.19-01-00021.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Risso S, DeFelice LJ, Blakely RD. Sodium-dependent GABA-induced currents in GAT1-transfected HeLa cells [comment]. J Physiol (Lond) 1996;490:691–702. doi: 10.1113/jphysiol.1996.sp021178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta. 1993;1144:249–263. doi: 10.1016/0005-2728(93)90109-s. [DOI] [PubMed] [Google Scholar]
- 28.Sesack SR, Pickel VM. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate–dopamine interactions. J Neurosci. 1992;12:1335–1350. doi: 10.1523/JNEUROSCI.12-04-01335.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Shafqat S, Velaz-Faircloth M, Guadano-Ferraz A, Fremeau RT. Molecular characterization of neurotransmitter transporters. Mol Endocrinol. 1993;7:1517–1529. doi: 10.1210/mend.7.12.7908408. [DOI] [PubMed] [Google Scholar]
- 30.Shafqat S, Velaz-Faircloth M, Henzi VA, Whitney KD, Yang-Feng T, Seldin MF, Fremeau RT. Human brain-specific l-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes. Mol Pharmacol. 1995;48:219–229. [PubMed] [Google Scholar]
- 31.Sonders M, Amara SG. Channels in transporters. Curr Opin Neurobiol. 1996;6:294–302. doi: 10.1016/s0959-4388(96)80111-5. [DOI] [PubMed] [Google Scholar]
- 32.Stevens BR, Kaunitz JD, Wright EM. Intestinal transport of amino acids and sugars: advances using membrane vesicles. Annu Rev Physiol. 1984;46:417–433. doi: 10.1146/annurev.ph.46.030184.002221. [DOI] [PubMed] [Google Scholar]
- 33.Velaz-Faircloth M, Guadano-Ferraz A, Henzi VA, Fremeau RT. Mammalian brain-specific l-proline transporter. Neuronal localization of mRNA and enrichment of transporter protein in synaptic plasma membranes. J Biol Chem. 1995;270:15755–15761. doi: 10.1074/jbc.270.26.15755. [DOI] [PubMed] [Google Scholar]